- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Pediatrics
American College of Rheumatology Revises Guidelines for Treatment of Juvenile Idiopathic Arthritis
March 04, 2022
The American College of Rheumatology (ACR) has published guidance regarding the management of juvenile idiopathic arthritis, with emphasis placed on the treatment of systemic JIA and oligoarthritis, as well as non-pharmacologic therapies.
Susan Shenoi, MBBS, MS: New Developments in Pediatric Rheumatology
February 23, 2022
Susan Shenoi, MBBS, MS, discusses the recent developments in pediatric rheumatology as well as new therapies and guidelines for treating juvenile idiopathic arthritis.
Improvements in Telehealth May Better Treat Pediatric Rheumatic Diseases
February 02, 2022
As telehealth is an emerging and rapidly changing form of pediatric rheumatology care, engaging patients, caregivers, and rheumatologists will help streamline care to improve satisfaction and overall experience.
Insufficient Efficacy of Fatigue Interventions for Pediatric Rheumatic Conditions
August 05, 2021
Although it is assumed that fatigue is related to inflammation, disease activity, or treatment with drugs such as Methotrexate, it can affect children independent of disease activity and impacted by psychosocial factors.
Guidelines for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic
June 23, 2021
The American College of Rheumatology has updated its treatment guidelines for the management of pediatric rheumatic disease during the COVID-19 pandemic. The guideline includes 33 final guidance recommendations, 8 of which received moderate-to-high task force consensus.
Genomic Risk Scores May Enhance JIA Diagnosis
October 05, 2020
In juvenile idiopathic arthritis, predictive genomic risk scores may enhance current diagnosis protocols, prioritizing higher-risk patients for follow-up and reducing treatment delays, according to a study published this month in Annals of Rheumatic Diseases.
Golimumab Approved for Pediatric Forms of Juvenile Arthritis and Psoriatic Arthritis
September 30, 2020
Golimumab (Simponi Aria, Janssen/J&J) has been approved by the U.S. Food and Drug Administration for two pediatric conditions:active pediatric juvenile idiopathic arthritis (JIA) and active pediatric psoriatic arthritis.
Image IQ: Infant with skin peeling
January 31, 2020
A 20-month-old boy with skin peeling, a strawberry red tongue and swelling of the hands and feet. Can you diagnose this patient?
FDA Approves First-Ever Treatment for Pediatric GPA, MPA
December 20, 2019
The U.S. Food and Drug Administration has approved rituximab (Rituxan, Genentech) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids, to fulfil an unmet medical need for these rare and serious diseases in children.
FDA Approves New Treatment for Rare Pediatric Vasculitis
October 01, 2019
The U.S. Food and Drug Administration has approved rituximab (Rituxan, Genentech) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids.